ArticleActa neurochirurgica2026
Treatment-naïve lung cancer presenting with spinal metastases: a national study of survival, surgery, and the role of predictive biomarkers.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSpinal metastasis as the first manifestation of lung cancer, presents challenges in diagnosis, prognosis, and treatment planning. This study aims to evaluate postoperative survival outcomes and to identify prognostic factors in treatment-naïve patients undergoing surgery for spinal metastases, focusing on clinical and molecular variables.
methodsThis retrospective cohort study included 149 patients who underwent surgery for spinal metastases from lung cancer between 2011 and 2023. Data were obtained from the Swedish National Register for Spine Surgery (Swespine) and the Swedish National Lung Cancer Register (SNLCR). Patients were grouped based on whether spinal metastasis was the initial manifestation of lung cancer or occurred during known disease. Kaplan-Meier analysis and Cox proportional hazards models were used to assess postoperative survival and prognostic factors.
resultsOf the 149 patients, 114 (77%) presented with spinal metastasis as the initial sign of lung cancer. Median survival in this group was 6 months, compared to 3 months in patients with a prior confirmed lung cancer diagnosis (p = 0.022). In the initial presentation group, longer survival after surgery was observed in patients with predictive biomarkers (8 vs. 5 months, p = 0.003), preserved ambulatory function (8 vs. 3 months, p = 0.002), and better WHO performance status (p < 0.001). In multivariable analysis, biomarker status, WHO performance status, ambulatory function, and age were independently associated with post-operative survival.
conclusionPatients undergoing surgery for spinal metastases as the initial manifestation of lung cancer form a distinct subgroup. Early functional and molecular assessment may improve patient selection and surgical outcome in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.